CY1120740T1 - Βελτιωμενα ευλογοϊικα εμβολια - Google Patents
Βελτιωμενα ευλογοϊικα εμβολιαInfo
- Publication number
- CY1120740T1 CY1120740T1 CY181100859T CY181100859T CY1120740T1 CY 1120740 T1 CY1120740 T1 CY 1120740T1 CY 181100859 T CY181100859 T CY 181100859T CY 181100859 T CY181100859 T CY 181100859T CY 1120740 T1 CY1120740 T1 CY 1120740T1
- Authority
- CY
- Cyprus
- Prior art keywords
- blessing
- vaccines
- improved
- vectors
- initiating
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title 1
- 239000013598 vector Substances 0.000 abstract 2
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000000977 initiatory effect Effects 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Virology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2013/055409 WO2014139587A1 (en) | 2013-03-15 | 2013-03-15 | Improved poxviral vaccines |
| PCT/IB2014/059802 WO2014141176A1 (en) | 2013-03-15 | 2014-03-14 | Improved poxviral vaccines |
| EP14723475.1A EP2968493B1 (en) | 2013-03-15 | 2014-03-14 | Improved poxviral vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1120740T1 true CY1120740T1 (el) | 2019-12-11 |
Family
ID=47882194
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY181100859T CY1120740T1 (el) | 2013-03-15 | 2018-08-14 | Βελτιωμενα ευλογοϊικα εμβολια |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US20160000904A1 (enExample) |
| EP (1) | EP2968493B1 (enExample) |
| JP (1) | JP6702725B2 (enExample) |
| CN (2) | CN105307674A (enExample) |
| BE (1) | BE1021192B1 (enExample) |
| BR (1) | BR112015023524B1 (enExample) |
| CA (1) | CA2907026A1 (enExample) |
| CY (1) | CY1120740T1 (enExample) |
| DK (1) | DK2968493T3 (enExample) |
| ES (1) | ES2685922T3 (enExample) |
| HR (1) | HRP20181376T1 (enExample) |
| HU (1) | HUE040189T2 (enExample) |
| LT (1) | LT2968493T (enExample) |
| PL (1) | PL2968493T3 (enExample) |
| PT (1) | PT2968493T (enExample) |
| SI (1) | SI2968493T1 (enExample) |
| WO (2) | WO2014139587A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10576143B2 (en) | 2013-03-15 | 2020-03-03 | Glaxosmithkline Biologicals Sa | Poxviral vaccines |
| WO2014139587A1 (en) | 2013-03-15 | 2014-09-18 | Okairòs Ag | Improved poxviral vaccines |
| GB201321384D0 (en) * | 2013-12-04 | 2014-01-15 | Isis Innovation | Molecular adjuvant |
| WO2017025782A1 (en) * | 2014-09-17 | 2017-02-16 | Glaxosmithkline Biologicals Sa | Improved poxviral vaccines |
| DK3294326T3 (da) | 2015-05-15 | 2021-05-31 | Curevac Ag | Prime-boost-regimer indbefattende indgivelse af mindst én mrna-konstruktion |
| MX2019002178A (es) * | 2016-08-23 | 2019-09-18 | Glaxosmithkline Biologicals Sa | Peptidos de fusion con antigenos enlazados a fragmentos cortos de cadena invariante (cd74). |
| GB201704417D0 (en) | 2017-03-20 | 2017-05-03 | Univ Copenhagen | Improved li vaccine adjuvant |
| US20200230220A1 (en) * | 2017-07-12 | 2020-07-23 | Nouscom Ag | Neoantigen vaccine composition for treatment of cancer |
| GB201721068D0 (en) | 2017-12-15 | 2018-01-31 | Glaxosmithkline Biologicals Sa | Hepatitis B immunisation regimen and compositions |
| GB201721069D0 (en) | 2017-12-15 | 2018-01-31 | Glaxosmithkline Biologicals Sa | Hepatitis B Immunisation regimen and compositions |
| GB201812647D0 (en) * | 2018-08-03 | 2018-09-19 | Chancellor Masters And Scholars Of The Univ Of Oxford | Viral vectors and methods for the prevention or treatment of cancer |
| BR112021000965A2 (pt) | 2018-08-07 | 2021-04-27 | Glaxosmithkline Biologicals S.A. | processos e vacinas |
| EP3897846A1 (en) * | 2018-12-21 | 2021-10-27 | GlaxoSmithKline Biologicals SA | Methods of inducing an immune response |
| BR112021017584A2 (pt) | 2019-03-05 | 2021-11-09 | Glaxosmithkline Biologicals Sa | Regime e composições de imunização contra hepatite b |
| CN111057716B (zh) * | 2019-07-27 | 2022-04-15 | 中国人民解放军军事科学院军事医学研究院 | 用于包装重组人4型腺病毒的单质粒载体系统及其应用 |
| WO2024133160A1 (en) | 2022-12-19 | 2024-06-27 | Glaxosmithkline Biologicals Sa | Hepatitis b compositions |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1272179B (it) | 1994-02-23 | 1997-06-16 | Angeletti P Ist Richerche Bio | Metodologia per riprodurre in vitro l'attivita' proteolitica della proteasi ns3 del virus hcv. |
| IT1278077B1 (it) | 1995-05-25 | 1997-11-17 | Angeletti P Ist Richerche Bio | Metodologia per riprodurre in vitro le attivita' di rna polimerasi rna-dipendente e di nucleotidiltransferasi terminale codificate dal |
| GB9711957D0 (en) * | 1997-06-09 | 1997-08-06 | Isis Innovation | Methods and reagents for vaccination |
| JP4475561B2 (ja) | 2001-10-11 | 2010-06-09 | メルク・シャープ・エンド・ドーム・コーポレイション | Ｃ型肝炎ウイルスワクチン |
| UA82479C2 (uk) * | 2002-05-16 | 2008-04-25 | Бавариан Нордика А/С | Міжгенні регіони як сайти вставки в геном модифікованого вірусу коров'ячої віспи ankara (mva) |
| JP4814800B2 (ja) | 2004-01-23 | 2011-11-16 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | チンパンジーアデノウイルスワクチン担体 |
| SI1957528T1 (sl) | 2005-11-30 | 2013-02-28 | University Of Copenhagen | Nukleotidno cepivo |
| SI2865387T1 (sl) | 2008-11-21 | 2019-10-30 | Kobenhavns Univ University Of Copenhagen | Primiranje imunskega odziva |
| HUE039908T2 (hu) | 2009-02-02 | 2019-02-28 | Glaxosmithkline Biologicals Sa | Majom adenovírusból származó nukleinsav- és aminosav-szekvenciák, azt tartalmazó vektorok és alkalmazásuk |
| US10576143B2 (en) * | 2013-03-15 | 2020-03-03 | Glaxosmithkline Biologicals Sa | Poxviral vaccines |
| WO2014139587A1 (en) | 2013-03-15 | 2014-09-18 | Okairòs Ag | Improved poxviral vaccines |
| GB201321384D0 (en) | 2013-12-04 | 2014-01-15 | Isis Innovation | Molecular adjuvant |
| MX2019002178A (es) | 2016-08-23 | 2019-09-18 | Glaxosmithkline Biologicals Sa | Peptidos de fusion con antigenos enlazados a fragmentos cortos de cadena invariante (cd74). |
-
2013
- 2013-03-15 WO PCT/EP2013/055409 patent/WO2014139587A1/en not_active Ceased
-
2014
- 2014-03-14 HU HUE14723475A patent/HUE040189T2/hu unknown
- 2014-03-14 US US14/770,510 patent/US20160000904A1/en not_active Abandoned
- 2014-03-14 WO PCT/IB2014/059802 patent/WO2014141176A1/en not_active Ceased
- 2014-03-14 CN CN201480015680.2A patent/CN105307674A/zh active Pending
- 2014-03-14 EP EP14723475.1A patent/EP2968493B1/en active Active
- 2014-03-14 CN CN201811100700.2A patent/CN109182378A/zh active Pending
- 2014-03-14 BE BE2014/0166A patent/BE1021192B1/fr not_active IP Right Cessation
- 2014-03-14 HR HRP20181376TT patent/HRP20181376T1/hr unknown
- 2014-03-14 JP JP2015562528A patent/JP6702725B2/ja not_active Expired - Fee Related
- 2014-03-14 DK DK14723475.1T patent/DK2968493T3/en active
- 2014-03-14 SI SI201430827T patent/SI2968493T1/sl unknown
- 2014-03-14 PT PT14723475T patent/PT2968493T/pt unknown
- 2014-03-14 ES ES14723475.1T patent/ES2685922T3/es active Active
- 2014-03-14 BR BR112015023524-7A patent/BR112015023524B1/pt not_active IP Right Cessation
- 2014-03-14 PL PL14723475T patent/PL2968493T3/pl unknown
- 2014-03-14 CA CA2907026A patent/CA2907026A1/en active Pending
- 2014-03-14 LT LTEP14723475.1T patent/LT2968493T/lt unknown
-
2017
- 2017-12-20 US US15/848,100 patent/US10588961B2/en active Active
-
2018
- 2018-08-14 CY CY181100859T patent/CY1120740T1/el unknown
-
2020
- 2020-02-05 US US16/782,268 patent/US11278614B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20200164061A1 (en) | 2020-05-28 |
| CN109182378A (zh) | 2019-01-11 |
| CN105307674A (zh) | 2016-02-03 |
| US10588961B2 (en) | 2020-03-17 |
| PL2968493T3 (pl) | 2018-11-30 |
| WO2014139587A1 (en) | 2014-09-18 |
| SI2968493T1 (sl) | 2018-12-31 |
| BR112015023524B1 (pt) | 2023-10-31 |
| PT2968493T (pt) | 2018-10-03 |
| JP2016510989A (ja) | 2016-04-14 |
| US11278614B2 (en) | 2022-03-22 |
| EP2968493A1 (en) | 2016-01-20 |
| BR112015023524A2 (pt) | 2017-10-24 |
| ES2685922T3 (es) | 2018-10-15 |
| LT2968493T (lt) | 2018-09-10 |
| JP6702725B2 (ja) | 2020-06-03 |
| HUE040189T2 (hu) | 2019-02-28 |
| US20180125968A1 (en) | 2018-05-10 |
| EP2968493B1 (en) | 2018-06-13 |
| US20160000904A1 (en) | 2016-01-07 |
| DK2968493T3 (en) | 2018-09-17 |
| HRP20181376T1 (hr) | 2018-10-19 |
| WO2014141176A1 (en) | 2014-09-18 |
| BE1021192B1 (fr) | 2016-10-21 |
| CA2907026A1 (en) | 2014-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1121934T1 (el) | Αντισωματα anti-fcrn | |
| CY1123563T1 (el) | Ανοσογονικα wt-1 πεπτιδια και μεθοδοι χρησης αυτων | |
| JOP20200091A1 (ar) | جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري | |
| CY1124867T1 (el) | Αντισωματα μονης περιοχης που κατευθυνονται εναντι ενδοκυτταρικων αντιγονων | |
| CY1122214T1 (el) | Αντισωματα ειδικα για ton fcrn | |
| CY1125392T1 (el) | Συνθεσεις και μεθοδοι γλυζυλιωσης πρωτεϊνων | |
| CY1125084T1 (el) | Εμβολια νουκλεϊκου οξεος | |
| CY1123769T1 (el) | Νουκλεϊκα οξεα για την αγωγη αλλεργιων | |
| CY1124106T1 (el) | Συνθεσεις μεταφορεα-αντισωματος και μεθοδοι παρασκευης και χρησης αυτων | |
| CY1125387T1 (el) | Αντιγονα, διαβιβαστες, συνθεσεις του ιου της ανθρωπινης ανοσοανεπαρκειας, και μεθοδοι χρησης τους | |
| CY1123403T1 (el) | Τροποποιημενα κυτταρα ξενιστες και χρησεις αυτων | |
| CY1124979T1 (el) | Κατασκευασματα πρωτεϊνης uspa2 και χρησεις αυτων | |
| MX376235B (es) | Antígenos asociados a próstata y regímenes de inmunoterapia basados en vacuna. | |
| EA201690504A1 (ru) | Антигенсвязывающие белки к gitr | |
| CY1121895T1 (el) | Σκευασματα διαλυματος κατασκευασμενων αντισωματων anti-il-23p19 | |
| CY1121964T1 (el) | Αντισωματα εναντιον toy csf-1r | |
| BR112015023524A2 (pt) | vacinas poxvirais melhoradas | |
| EA201691631A1 (ru) | Иммунотерапия рака с применением комбинации местной и системной иммунной стимуляции | |
| MX2013008836A (es) | Moleculas de acido nucleico que codifican novedosos antigenos de herpes, vacunas que las comprenden y metodos para su uso. | |
| MX2015013065A (es) | Proteinas f de rsv de prefusion y su uso. | |
| EA201790294A1 (ru) | Средства на основе флагеллина и применения, включающие эффективную вакцинацию | |
| CY1124707T1 (el) | Συνθεσεις και μεθοδοι για την επαγωγη ενισχυμενης ανοσοαποκρισης με χρηση φορεων ιων poxvirus (ευλογοϊων) | |
| EA201891124A2 (ru) | Новые мукозные адъюванты и системы доставки | |
| EA201790239A1 (ru) | Молекула-носитель для антигенов | |
| BR112017023131A2 (pt) | anticorpos anti- fcrn |